Dat	<b>e</b> : 15. maj 2024		
You	ır name: René Ernst Niels	sen	
Ma	nuscript title: Letter t	to the editor	
	nuscript number (if known	):	
are r third comi list a	elated to the content of yo parties whose interests ma mitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the contend does not necessarily in est, it is preferable that yo	
	uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of hypertensive medication, ex	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with	
		whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) ining of the work  None	(e.g., if payments were made to you or to your institution)
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Ining of the work  None	(e.g., if payments were made to you or to your institution)

S   Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events   Disuka UK   Webinar (educational lecture)   Janssen-Cilag   Educational lecture   Disuba DK   Educational lecture   Education	4	Consulting fees	<b>⊠</b> None		
Icctures, presentations, speakers bureaus, manuscript writing or educational events   Otsuka UK   Mebinar (educational lecture   Ianssen-Cilag   Educational lecture   Educational lecture   Ianssen-Cilag   Ianss					
Icctures, presentations, speakers bureaus, manuscript writing or educational events   Otsuka UK   Mebinar (educational lecture   Ianssen-Cilag   Educational lecture   Educational lecture   Ianssen-Cilag   Ianss					
Icctures, presentations, speakers bureaus, manuscript writing or educational events   Otsuka UK   Mebinar (educational lecture   Ianssen-Cilag   Educational lecture   Educational lecture   Ianssen-Cilag   Ianss	5	Payment or honoraria for	None		
speakers bureaus, manuscript writing or educational events    Common to be provided by the pro	,	-		Webinar (educational lecture)	
manuscript writing or educational events    Disuka DK   Educational lecture		· · · · · · · · · · · · · · · · · · ·		·	
Educational lecture   Lundbeck DK   Webinar (educational lecture)					
Lundbeck UK Boehringer-Ingelheim Teva Educational lecture  Educational lecture  Educational lecture  Educational lecture  8 Payment for expert testimony  None  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board    Company   C		educational events			
Boehringer-Ingelheim Teva Educational lecture  Teva Educational lecture  8 Payment for expert testimony					
Teva Educational lecture    Payment for expert testimony					
6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services    None					
testimony    Support for attending meetings and/or travel			1010	Eddod for factors	
testimony    Support for attending meetings and/or travel	_	_	T		
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  None  None  None    None     President	6		■ None		
Receipt of equipment, materials, drugs, medical writing, gifts or other services   None   None		testimony			
Receipt of equipment, materials, drugs, medical writing, gifts or other services   None   None					
Receipt of equipment, materials, drugs, medical writing, gifts or other services   None   None	7	Support for attending	⊠ None		
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    None			Z None		
Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    None		g ,			
Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    None					
9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    None	8		☑ None		
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  15 Isafety Monitoring Board Janssen-Cilag Scientific Advisory Board  16 International Group for the Study of Lithium Tresident  17 International Group for the Study of Lithium Treated Patients (IGSLi)  18 International Group for the Study of Lithium Treated Patients (IGSLi)  19 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  11 Stock or stock options  2 None  2 None		pending			
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  15 Isafety Monitoring Board Janssen-Cilag Scientific Advisory Board  16 International Group for the Study of Lithium Tresident  17 International Group for the Study of Lithium Treated Patients (IGSLi)  18 International Group for the Study of Lithium Treated Patients (IGSLi)  19 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  11 Stock or stock options  2 None  2 None					
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  15 Isafety Monitoring Board Janssen-Cilag Scientific Advisory Board  16 International Group for the Study of Lithium Tresident  17 International Group for the Study of Lithium Treated Patients (IGSLi)  18 International Group for the Study of Lithium Treated Patients (IGSLi)  19 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  10 International Group for the Study of Lithium Treated Patients (IGSLi)  11 Stock or stock options  2 None  2 None			□ None		
or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    None     None	9	Participation on a Data	□ None		
role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options    None     None     None	9			Scientific Advisory Board	
role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options    None     None     None	9	Safety Monitoring Board		Scientific Advisory Board	
society, committee or advocacy group, paid or unpaid  11 Stock or stock options    None		Safety Monitoring Board or Advisory Board		Scientific Advisory Board	
advocacy group, paid or unpaid  Treated Patients (IGSLi)  Treated Patients (IGSLi)  11 Stock or stock options  None  None  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  None  None		Safety Monitoring Board or Advisory Board  Leadership or fiduciary	Janssen-Cilag	Scientific Advisory Board	
unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  None		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board,	Janssen-Cilag  None International Group for		
11 Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  None  None  None		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or	□ None International Group for the Study of Lithium		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	□ None International Group for the Study of Lithium		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	□ None International Group for the Study of Lithium		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	□ None International Group for the Study of Lithium		
materials, drugs, medical writing, gifts or other services  13 Other financial or non-		Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	□ None International Group for the Study of Lithium		
materials, drugs, medical writing, gifts or other services  13 Other financial or non-	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)		
materials, drugs, medical writing, gifts or other services  13 Other financial or non-	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)		
materials, drugs, medical writing, gifts or other services  13 Other financial or non-	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)		
writing, gifts or other services  13 Other financial or non-  None	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)  None		
services  13 Other financial or non-  Mone	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)  None		
	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)  None		
	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)  None		
financial interests	10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	Janssen-Cilag  None International Group for the Study of Lithium Treated Patients (IGSLi)  None		
	11 12	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	□ None International Group for the Study of Lithium Treated Patients (IGSLi)  ■ None  None		
	11 12	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	□ None International Group for the Study of Lithium Treated Patients (IGSLi)  ■ None  None		
	11 12	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	□ None International Group for the Study of Lithium Treated Patients (IGSLi)  ■ None  None		

 $oxed{\boxtimes}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.				

Dat	<b>e</b> : 15. maj 2024		
You	ı <b>r name</b> : Torben Albert D	evantier	
Mai	nuscript title: Letter	to the editor	
	nuscript number (if known	):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the control does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of sypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript dideclare all relationships with manufacturers of not mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding,	☑ None	
	provision of study materials, medical writing, article processing charges, etc.)		
	provision of study materials, medical writing, article processing charges,		
	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this		Click TAB in last row to add extra rows
Time	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		Click TAB in last row to add extra rows
Time 2	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	None	Click TAB in last row to add extra rows
	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated in item #1 above).		Click TAB in last row to add extra rows
2	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	None     None     None	Click TAB in last row to add extra rows

4	Consulting fees	⊠ None
5	Payment or honoraria for	⊠ None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
	eddedional events	
6	Payment for expert	<b>⊠</b> None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or	M Name
٥	pending	⊠ None
	Pe9	
9	Participation on a Data	⊠ None
	Safety Monitoring Board or Advisory Board	
	or Advisory Board	
10	Leadership or fiduciary	⊠ None
	role in other board,	
	society, committee or	
	advocacy group, paid or unpaid	
	- 1	
11	Stock or stock options	⊠ None
12	Receipt of equipment,	⊠ None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	⊠ None
	financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	<b>e</b> : 16. maj 2024		
You	ır name: Rasmus W. Lich	nt	
Ma	nuscript title: Letter	to the editor	
	nuscript number (if known	):	
are r third comi	elated to the content of yo parties whose interests m	our manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of hypertensive medication, evaluation and the second	f hypertension, you should ven if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
<b>Tim</b> 1	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work  None	(e.g., if payments were made to you or to your institution)
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) nning of the work  None	(e.g., if payments were made to you or to your institution)

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	□ None  Lundbeck  Janssen-Cilag
	educational events	Teva
6	Payment for expert	<b>⊠</b> None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or	⊠ None
	pending	
9	Participation on a Data	⊠ None
	Safety Monitoring Board	
	or Advisory Board	
10	Leadership or fiduciary	⊠ None
	role in other board,	
	society, committee or	
	advocacy group, paid or unpaid	
	unpaiu	
11	Stock or stock options	⊠ None
12	Receipt of equipment,	⊠ None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	⊠ None
	financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 14,5,2024

Your name: SUNG STRAIZEN

Manuscript title: LETTEIL TO TITE GUITOL

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed)

Specifications/Comments (e.g., if payments were made to you or to your institution)

Time frame: Since the initial planning of the work

1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Click TAB in last row to add extra rows

Time frame: past 36 months

2 Grants or contracts from any None entity (if not indicated in item #1 above).

3 Royalties or licenses None

- 4 Consulting fees None
- 5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events
  - □ None

TANGA PHARM AS LUNBECH PHARM AS

- o Payment for expert testimony None
- 7 Support for attending meetings and/or travel

None

8 Patents planned, issued or pending

None

9 Participation on a Data Safety Monitoring Board or Advisory Board

None

- 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid
- 11 Stock or stock options W None
- 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services

None

13 Other financial or nonfinancial interests None

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal
Please save/export the filled in form as PDF before submitting
it to Ugeskrift for Læger or Danish Medical Journal.

ICMJE Disclosure Form (Feb2023): http://icmje.org

Ugeskrift for Læger / Danish Medical Journal

Page

Dat	<b>e</b> : 14. maj 2024		
You	ır name: Zoltan Kovacs		
Ma	nuscript title: Letter	to the Editor	
	nuscript number (if known		
are r third comi	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of hypertensive medication, evaluation	hypertension, you should wen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work  None	(e.g., if payments were made to you or to your institution)
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Ining of the work  None	(e.g., if payments were made to you or to your institution)

4	Consulting fees   None		
_	Dayment or honoraria for Malaura		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	<b>⊠</b> None	I
	educational events		
6	Payment for expert	<b>⊠</b> None	
	testimony		
7	Support for attending	□ None	
,	meetings and/or travel	None	Support for practice "Depressioned agence 2024"
	meetings and or traver	Janssen Neuroscience	Support for meeting "Depressionsdagene 2024"
8	Patents planned, issued or	<b>⊠</b> None	
	pending		
9	Participation on a Data	<b>⊠</b> None	
,	Safety Monitoring Board	⊠ None	T
	or Advisory Board		
10	Leadership or fiduciary	<b>⊠</b> None	
	role in other board,		
	society, committee or		
	advocacy group, paid or unpaid		
	апрага		
11	Stock or stock options	⊠ None	
42			
12	Receipt of equipment, materials, drugs, medical	<b>☑</b> None	Т
	writing, gifts or other		
	services		
13	Other financial or non-	⊠ None	
	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal